骨质疏松患者使用双膦酸盐与地舒单抗的颌骨坏死风险比较:台湾多机构回顾性队列研究
本多机构回顾性队列研究比较骨质疏松患者使用地舒单抗与双膦酸盐后长期颌骨坏死风险。倾向评分匹配后每组3665例,地舒单抗组颌骨坏死发生密度1.47 vs 双膦酸盐组2.49事件/1000人年,风险比0.581(95%CI 0.33-1.04,p=0.07)。用药2年后地舒单抗所致颌骨坏死可能性低于双膦酸盐,且差异随时间增加。
要点
- 匹配后地舒单抗组颌骨坏死发生密度1.47 vs 双膦酸盐组2.49事件/1000人年。
- 地舒单抗 vs 双膦酸盐的颌骨坏死风险比HR 0.581(95%CI 0.33-1.04,p=0.07)。
- 两组颌骨坏死累积发生率第1、2年相似(p=0.062),第3年起差异显著(p=0.022)。
核心结论
- 骨质疏松患者用药2年后,地舒单抗诱发颌骨坏死的可能性低于双膦酸盐,且差异随时间增加。
研究设计与样本
- 多机构回顾性队列研究,纳入2010年1月至2018年12月年龄>40岁的骨质疏松患者,按倾向评分匹配分为双膦酸盐组和地舒单抗组。
- 共纳入84,102例骨质疏松患者,其中8,962例符合一线用药纳入标准(地舒单抗n=3,823;双膦酸盐n=5,139)。
- 倾向评分匹配(1:1)后,双膦酸盐组和地舒单抗组各3,665例。
主要发现
- 地舒单抗组与双膦酸盐匹配组的颌骨坏死发生密度分别为1.47 vs 2.49事件/1000人年。
- 地舒单抗组 vs 双膦酸盐组的颌骨坏死风险比HR 0.581(95%CI 0.33-1.04,p=0.07)。
- 两组颌骨坏死累积发生率在用药第1年和第2年相似(p=0.062),但从第3年起显著不同(p=0.022)。
- 两组颌骨坏死的严重程度无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: In this multi-institutional retrospective cohort study, we compared the long-term risk of osteonecrosis of the jaw following the use of denosumab vs. bisphosphonates in osteoporotic patients. After 2-year use, the likelihood of osteonecrosis of the jaw is lower with denosumab compared to bisphosphonates, and the difference increases with time. PURPOSE: To compare the long-term risk of osteonecrosis of the jaw (ONJ) between osteoporotic patients treated with bisphosphonates (BPs) and denosumab. METHODS: This multi-institutional retrospective cohort study included patients aged > 40 years with osteoporosis between January 2010 and December 2018. Patients who met the eligibility criteria were divided into BPs and denosumab groups by propensity score matching (PSM). The risk of ONJ of denosumab vs. BPs was estimated using a Cox proportional hazards model and was described by the cumulative incidence rate using the Kaplan-Meier method. RESULTS: A total of 84,102 patients with osteoporosis were enrolled, among whom, 8962 were eligible for inclusion based on their first-line drug use (denosumab, n = 3,823; BPs, n = 5,139). Following PCM matching (1:1), the BPs and denosumab groups included 3665 patients each. The incidence density of ONJ in the denosumab and BPs matching groups was 1.47 vs. 2.49 events (per 1000 person-years), respectively. The hazard ratio of ONJ in the denosumab vs. BPs group was estimated as 0.581 (95% confidence interval: 0.33-1.04, p = 0.07). The cumulative incidence rates of ONJ in both groups were similar for the first and second years of drug use (p = 0.062), but significantly different from the third year onwards (p = 0.022). The severity of ONJ was not significantly different between the two groups. CONCLUSION: In osteoporotic patients, after 2 years of use, the likelihood of ONJ being induced by denosumab is lower than that of BPs, and the difference increases with time.
引用
- Liu FC, Luk KC, Chen YC, et al. Risk comparison of osteonecrosis of the jaw in osteoporotic patients treated with bisphosphonates vs. denosumab: a multi-institutional retrospective cohort study in Taiwan. Osteoporos Int. 2023. PMID: 37326685. doi:10.1007/s00198-023-06818-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。